STOCKS TELEGRAPH

Tag: Coronavirus Vaccine

  • Enlivex (NASDAQ: ENLV) Announces Positive Result Of Allocetra In COVID-19 Patients

    Enlivex (NASDAQ: ENLV) Announces Positive Result Of Allocetra In COVID-19 Patients

    Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has revealed today that the clinical trial of AllocetraTM has shown positive results in COVID-19 patients who were in critical condition. The company has conducted a clinical trial that included five patients, two patients were in critical condition and three patients were in severe condition. But following the treatment of Allocetra all the patients who were in critical and severe conditions were discharged from a hospital after an average of 5.5 days (severe) and 8.5 days (critical).

    The company has further disclosed that there were no severe adverse events were reported relating to the administration of AllocetraTM in the patients, and the therapy was well-tolerated. Other therapies such as plasma-based anti-bodies were used for the treatment of patients in moderate conditions while the company has treated COVID-19 patients who were in severe/critical condition with Allocetra.

    Enlivex Therapeutics Ltd. has believed that the treatment with Allocetra will fill the gap that currently exists in treating severe or critical COVID-19 patients. The biotechnology company revealed that it is planning to recruit more patients who are in severe/critical condition to further check the safety and efficacy of Allocetra after receiving regulatory approval.

    Enlivex Therapeutics Ltd. (NASDAQ: ENLV) shares were trading up 21.22 % at $5.94 at the time of writing on Wednesday. Enlivex Therapeutics Ltd.’s share price went from a low point around $3.59 to briefly over $28.40 in the past 52 weeks, though shares have since pulled back to $5.94. It has moved up 65.46% from its 52-weeks low and moved down -79.08% from its 52-weeks high. ENLV market cap has remained high, hitting $78.23M at the time of writing.

    Head of the Critical Care Medicine Unit at Hadassah Hospital in Israel, and the lead investigator of both the COVID-19 trial and a recently-executed Phase Ib clinical trial of AllocetraTM in sepsis patients, Prof. Vernon van Heerden revealed that the candidate of Enlivex has the potential to treat the COVID-19 patients who are in critical or severe condition. Prof. Vernon said that the five patients with COVID-19 and 10 patients with sepsis have shown the encouraging results in the phase 1b study of Allocetra.

    Enlivex revealed that it is a great opportunity for the company to contribute towards effort aimed at controlling the spread of novel coronavirus. The company will continue its struggle to combat the spread of COVID-19. It is anticipated that the Phase IIb trial of Allocetra will commence in the fourth quarter of the company.

     

  • Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

    Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

    All the companies involved in the production of the coronavirus vaccine, iBio is far behind from its competitors in the vaccine trial. The company has earlier revealed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of coronavirus infection. But the company has not provided any promising result related to its coronavirus vaccine candidate nor it entered into the human trial of its vaccine candidate.

    iBio, a biotech innovator and biologics contract manufacturing organization has earlier made the various claims about its vaccine candidate. It has claimed exclusive worldwide license agreement on a cure called ACE2-Fc from Planet  Biotechnology. Not only this, but the company also claimed that its FastPharming system has the ability to produce vaccines quickly using plant cells.

    So, it is better to avoid iBio for the coronavirus vaccine until it catches up and moves its coronavirus vaccine candidate into human trials. Many companies including Moderna, Novavax, AstraZeneca, and Pfizer all are currently in human trials of their vaccine candidate. But iBio, Inc. is still in the lab and far behind from its competitors. To reach the market human trials are necessary.

    Shares of iBio, Inc. (IBIO) traded up 9.30% as it gained +0.20 on Thursday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $0.05 and a high range of $7.45. iBio has moved up 4600.00% from its 52-weeks low and moved down -68.46% from its 52-weeks high. Looking at its profitability, its return on assets and investment is -108.70%, and -57.60%, respectively. If we turn our focus on its liquidity, its current ratio is 1.70. iBio, Inc. market capitalization has remained high, hitting $420.46 million at the time of writing.

    There are various sciences behind iBio stock. If we look at the political stories, Donald Trump is looking for a vaccine before November. Similarly, from a business point of view, billions were given to the companies for the products which are not ready for the market yet. If we turn our focus on iBio, it only claims that it has a vaccine candidate but that is still in the lab.

    It has not advanced it trial to humans which is necessary. iBio stocks soared after it revealed about the FastPharming. But it is not clear yet whether the company has a vaccine or not or it is the trick of the company to excite its stock. So, it is better to avoid the stock of iBio for the coronavirus vaccine until it starts a human trial.

  • Should You Invest In Inovio Pharmaceuticals (NASDAQ: INO)?

    Should You Invest In Inovio Pharmaceuticals (NASDAQ: INO)?

    Inovio Pharmaceuticals, Inc. (NASDAQ: INO), a biotechnology company has recorded an increase of 35.88% in its shares price as it has gained +4.89 on Wednesday. Inovio Pharmaceuticals has earlier participated in H.C. Wainwright 22nd Annual Global Investment Conference on September 14 where its CEO J. Joseph Kim has made two statements that excited its investors.

    CEO J. Joseph disclosed that the Phase 1 study of its coronavirus vaccine candidate INO-4800 is currently in the peer review. He also revealed that the Inovio will soon announce the result of peer review in the coming weeks. Secondly, Inovio’s CEO said that the company is planning to start phase 2/3 testing for its investigational vaccine. The biotech company is waiting for the FDA approval for phase 2/3 which the company expects will happen soon. Inovio said that it is confident that it will receive the funding for the upcoming trials of the vaccine.

    Inovio Pharmaceuticals is scheduled to participate in the upcoming two conferences including Cantor Global Healthcare Conference on September 17 and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit which will take place on September 23. Investors expected that the biotechnology company will announce the exciting news soon.

    Inovio Pharmaceuticals (NASDAQ: INO) shares were trading up 35.88% at $18.52 at the time of writing on Thursday.  INO share price went from a low point around $1.91 to briefly over $33.79 in the past 52 weeks. It has moved up 867.10% from its 52-weeks low and moved down -45.19% from its 52-weeks low. If we look at its liquidity, it has a current ratio of 10.10. Inovio market cap has remained high, hitting $2.99 billion at the time of writing.

    The company has earlier shared the result from the Phase 1 clinical trial of the coronavirus vaccine candidate but the industry investors were not satisfied with the result as the company didn’t give any details about immune responses in patients. But it is expected that the upcoming peer review could clear the doubts of industry observers.

    Shares of Inovio Pharmaceuticals has experienced an unusual options activity on Wednesday trading session. The large volume is one option activity that is considered to be unusual. The volume of options activity means the number of shares contracts traded for a day. INO has experienced bullish sentiments which means to buy at/near ask price or a put is sold at/near bid price.

    Previously, Inovio Pharmaceuticals has signed a contract with Thermo Fisher Scientific for the development of a coronavirus vaccine candidate, INO-4800. Inovio is planning to make the 100 million doses of INO-4800 by 2021 after receiving FDA approval.

  • Is Pfizer Inc. (NYSE: PFE) A Good Investment?

    Is Pfizer Inc. (NYSE: PFE) A Good Investment?

    Shares of Pfizer Inc. (NYSE: PFE) traded up 2.61% after gaining +0.94 on Monday as it may be the first to disclose the late-stage study result from its trials with partner BioNTech SE. Pfizer Inc. is currently conducting one of the most advanced trials of a vaccine for novel coronavirus.

    It has commenced the Phase 2/3 study of BNT162b2, a most advanced coronavirus vaccine candidate in July. Almost 30,000 participants were enrolled in the trial who received two doses of the vaccine candidate.

    Pfizer CEO Albert Bourla revealed that the FDA committee will gather to discuss vaccines on Oct 22. CEO said that the company has a deep understanding of this matter and it will be able to present the efficacy data of Phase 3 before the end of October.

    He said that the company is not bound to any deadline. Albert Bourla said that FDA is searching for companies to review their vaccines that are at least 50% effective. Pfizer is hoping for a better result as its Phase 3 trial with 30,000 people is almost completed.

    Goldman Sachs labeled this a vaccine trade as the investors were attracting towards stocks that were developing a vaccine or any treatment of diseases and they dumped the stock soon after hearing the good news. The same thing happened with Gilead Sciences as its shares tumbled down after it has got the regulatory approval for its antiviral medicine of COVID-19.

    Pfizer Inc. (NYSE: PFE) share price went from a low point around $27.88 to briefly over $40.97 in the past 52 weeks, though shares have since pulled back to $37.01. Pfizer Inc. has moved up 32.75% from its 52-weeks low and moved down -9.67% from its 52-weeks high. Pfizer Inc.’s market cap has remained high, hitting $203.27 billion at the time of writing. If we look at its liquidity, it has a current ratio of 1.40.

    Pfizer Inc and BioNTech SE have recently disclosed that they striving to secure the approval of the US FDA to expand the late-stage clinical trial of their COVID-19 vaccine. Earlier, Pfizer has enrolled the 30,000 participants in the trial but now it is looking for the trial which will enroll 44,000 volunteers as the company is trying to add the young population in the late-stage study.

    Previously, the US Government has revealed that it would pay $1.95 billion to companies for the supply of 100 million doses of vaccine if it received regulatory approval. CEO Pfizer also disclosed that the company has invested $1.5 billion for the development of a vaccine and if the trial is not successful it is painful for the company.